Tags

Type your tag names separated by a space and hit enter

[The macular pigment: short- and intermediate-term changes of macular pigment optical density following supplementation with lutein and zeaxanthin and co-antioxidants. The LUNA Study].
Ophthalmologe 2009; 106(1):29-36O

Abstract

BACKGROUND

How long do the elevated concentrations of macular pigment persist after stopping supplementation with lutein and zeaxanthin?

METHODS

One hundred eight (108) probands with and without age-related macular degeneration (68 female, 40 male, age 51-87 years) received a supplement containing 12 mg lutein and 1 mg zeaxanthin once per day (Ocuvite lutein) for 6 months. Analysis of macular pigment optical density (MPOD) was performed during the period of supplementation and again 3, 6, and 9 months following discontinuation of the supplement. A control group of 28 subjects received no dietary supplement.

RESULTS

At baseline, the mean MPOD at 0.5 degrees was 0.50 in the supplemented group. Following supplementation, values rose, and 3 months after discontinuation of supplementation the highest levels of MPOD0.5 degrees (0.59 ODU) were detected (increase of +0.1 ODU, (p<0.001). Six months after supplement discontinuation, a slight decrease of mean MPOD0.5 degrees appeared (to 0.54 ODU), followed again by a slight increase 3 months later (to 0.57 ODU). An increment of MPOD0.5 degrees in the control group was not significant (0.03 ODU, p=0.15).

DISCUSSION

Supplementation of lutein and zeaxanthin leads to an increase of MPOD0.5 degrees . This effect outlasts the duration of intake, and 9 months after supplementation was stopped, the mean MPOD0.5 degrees was still elevated compared with baseline levels. A longer follow-up subsequent to stopping supplementation might clarify whether the values decrease over time or whether a plateau of elevated MPOD levels is reached. High doses of lutein and zeaxanthin seem to be necessary to increase macular pigment density in the retina; afterwards, the amount of carotenoids needed to maintain high concentrations seems to be covered by daily food.

Authors+Show Affiliations

St. Franziskus Hospital, Münster, Deutschland. meiketri@aol.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
English Abstract
Journal Article

Language

ger

PubMed ID

18551295

Citation

Zeimer, M, et al. "[The Macular Pigment: Short- and Intermediate-term Changes of Macular Pigment Optical Density Following Supplementation With Lutein and Zeaxanthin and Co-antioxidants. the LUNA Study]." Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft, vol. 106, no. 1, 2009, pp. 29-36.
Zeimer M, Hense HW, Heimes B, et al. [The macular pigment: short- and intermediate-term changes of macular pigment optical density following supplementation with lutein and zeaxanthin and co-antioxidants. The LUNA Study]. Ophthalmologe. 2009;106(1):29-36.
Zeimer, M., Hense, H. W., Heimes, B., Austermann, U., Fobker, M., & Pauleikhoff, D. (2009). [The macular pigment: short- and intermediate-term changes of macular pigment optical density following supplementation with lutein and zeaxanthin and co-antioxidants. The LUNA Study]. Der Ophthalmologe : Zeitschrift Der Deutschen Ophthalmologischen Gesellschaft, 106(1), pp. 29-36. doi:10.1007/s00347-008-1773-4.
Zeimer M, et al. [The Macular Pigment: Short- and Intermediate-term Changes of Macular Pigment Optical Density Following Supplementation With Lutein and Zeaxanthin and Co-antioxidants. the LUNA Study]. Ophthalmologe. 2009;106(1):29-36. PubMed PMID: 18551295.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The macular pigment: short- and intermediate-term changes of macular pigment optical density following supplementation with lutein and zeaxanthin and co-antioxidants. The LUNA Study]. AU - Zeimer,M, AU - Hense,H W, AU - Heimes,B, AU - Austermann,U, AU - Fobker,M, AU - Pauleikhoff,D, PY - 2008/6/14/pubmed PY - 2009/8/6/medline PY - 2008/6/14/entrez SP - 29 EP - 36 JF - Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft JO - Ophthalmologe VL - 106 IS - 1 N2 - BACKGROUND: How long do the elevated concentrations of macular pigment persist after stopping supplementation with lutein and zeaxanthin? METHODS: One hundred eight (108) probands with and without age-related macular degeneration (68 female, 40 male, age 51-87 years) received a supplement containing 12 mg lutein and 1 mg zeaxanthin once per day (Ocuvite lutein) for 6 months. Analysis of macular pigment optical density (MPOD) was performed during the period of supplementation and again 3, 6, and 9 months following discontinuation of the supplement. A control group of 28 subjects received no dietary supplement. RESULTS: At baseline, the mean MPOD at 0.5 degrees was 0.50 in the supplemented group. Following supplementation, values rose, and 3 months after discontinuation of supplementation the highest levels of MPOD0.5 degrees (0.59 ODU) were detected (increase of +0.1 ODU, (p<0.001). Six months after supplement discontinuation, a slight decrease of mean MPOD0.5 degrees appeared (to 0.54 ODU), followed again by a slight increase 3 months later (to 0.57 ODU). An increment of MPOD0.5 degrees in the control group was not significant (0.03 ODU, p=0.15). DISCUSSION: Supplementation of lutein and zeaxanthin leads to an increase of MPOD0.5 degrees . This effect outlasts the duration of intake, and 9 months after supplementation was stopped, the mean MPOD0.5 degrees was still elevated compared with baseline levels. A longer follow-up subsequent to stopping supplementation might clarify whether the values decrease over time or whether a plateau of elevated MPOD levels is reached. High doses of lutein and zeaxanthin seem to be necessary to increase macular pigment density in the retina; afterwards, the amount of carotenoids needed to maintain high concentrations seems to be covered by daily food. SN - 1433-0423 UR - https://www.unboundmedicine.com/medline/citation/18551295/full_citation L2 - https://dx.doi.org/10.1007/s00347-008-1773-4 DB - PRIME DP - Unbound Medicine ER -